The Minnesota Department of Health (MDH) today announced that they are tracking a rise in tularemia cases in humans and in ...

There are signs in the new study and others that climate change is causing Alaska polar bears to become increasingly at risk of tularemia. The average 13.3% seroprevalence for the tested polar ...

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious ...

Advances in pathogen classification, enhanced diagnostic methodologies, and improved surveillance strategies have collectively contributed to refining our understanding of tularemia's transmission ...

Repeated lab tests detected the presence of tularemia, a deadly pathogen carried by rabbits. Soon, though, officials concluded there had been no attack. Advertisement ...

X-ray eyes peer deeper into deadly pathogen Tularemia is a rare but often lethal disease. It is caused by one of the most aggressive pathogens on earth, the bacterium Francisella tularensis.

About ATI-1701 ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with F. tularensis, the causative agent of tularemia and a top-priority biothreat.

Tularemia, also known as rabbit fever, can be life-threatening for people if not treated quickly, but most infections can be treated successfully with antibiotics, the CDC says.